22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Angiopoietin-2 (ANG2) regulates blood vessel remodeling in many pathological conditions through differential effects on Tie2 signaling. While ANG2 competes with ANG1 to inhibit Tie2, it can paradoxically also promote Tie2 phosphorylation (p-Tie2). A related paradox is that both inactivation and overactivation of Tie2 can result in vascular remodeling. Here, we reconciled these opposing actions of ANG2 by manipulating conditions that govern its actions in the vasculature. ANG2 drove vascular remodeling during Mycoplasma pulmonis infection by acting as a Tie2 antagonist, which led to p-Tie2 suppression, forkhead box O1 (FOXO1) activation, increased ANG2 expression, and vessel leakiness. These changes were exaggerated by anti-Tie2 antibody, inhibition of PI3K signaling, or ANG2 overexpression and were reduced by anti-ANG2 antibody or exogenous ANG1. In contrast, under pathogen-free conditions, ANG2 drove vascular remodeling by acting as an agonist, promoting high p-Tie2, low FOXO1 activation, and no leakage. Tie1 activation was strong under pathogen-free conditions, but infection or TNF-α led to Tie1 inactivation by ectodomain cleavage and promoted the Tie2 antagonist action of ANG2. Together, these data indicate that ANG2 activation of Tie2 supports stable enlargement of normal nonleaky vessels, but reduction of Tie1 in inflammation leads to ANG2 antagonism of Tie2 and initiates a positive feedback loop wherein FOXO1-driven ANG2 expression promotes vascular remodeling and leakage.

          Related collections

          Author and article information

          Contributors
          Journal
          J Clin Invest
          J. Clin. Invest
          J Clin Invest
          The Journal of Clinical Investigation
          American Society for Clinical Investigation
          0021-9738
          1558-8238
          22 August 2016
          1 September 2016
          1 December 2016
          : 126
          : 9
          : 3511-3525
          Affiliations
          [1 ]Department of Anatomy, Cardiovascular Research Institute, and UCSF Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
          [2 ]Wihuri Research Institute, Translational Cancer Biology Program, University of Helsinki, Helsinki, Finland.
          [3 ]Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA.
          [4 ]Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
          Author notes
          Address correspondence to: Donald M. McDonald, University of California, San Francisco, 513 Parnassus Avenue, Room S1349, San Francisco, California 94143-0452, USA. Phone: 415.476.2118; E-mail: donald.mcdonald@ 123456ucsf.edu .
          Author information
          http://orcid.org/0000-0002-0000-8091
          http://orcid.org/0000-0003-2652-0584
          Article
          PMC5004955 PMC5004955 5004955 84871
          10.1172/JCI84871
          5004955
          27548529
          aee8a927-c6c3-4ac1-bb6b-29275f8268f6
          Copyright © 2016, American Society for Clinical Investigation
          History
          : 30 September 2015
          : 24 June 2016
          Categories
          Research Article

          Comments

          Comment on this article